



Supplement to prospectus for admission of shares to trading on Nasdaq Stockholm and invitation to subscribe for shares in AddLife AB (publ)

IMPORTANT INFORMATION

This document is a translation of a Swedish prospectus supplement. Distribution of the Prospectus (defined below), the Prospectus Supplement (defined below), and this English translation thereof, as well as participation in the Offering (defined below), are subject to restrictions under law and other regulations in certain jurisdictions. No action has been taken and measures will not be taken to permit a public offering in any other jurisdiction than Sweden. The Offering is not made to persons resident in the United States (including its territories and provinces, every state in the United States and the District of Columbia ("USA")), Canada, Australia, Japan, Hong Kong, New Zealand, Switzerland, Singapore, South Africa or in any other jurisdictions where participation would require additional prospectuses, registration or other measures than those required by Swedish law. Consequently the Prospectus, the Prospectus Supplement, this English translation and other documents relating to the Offering may not be distributed in or into the aforementioned countries or any other country or any other jurisdiction in which such distribution or the Offering require such measures or would otherwise be in conflict with applicable rules. Subscription for shares in violation of the above restrictions may be void. Recipients of copies of the Prospectus Supplement and this English translation must inform themselves about and comply with such restrictions. Actions in violation of these restrictions may constitute a violation of applicable securities laws.

Existing and newly issued shares in AddLife have not been and will not be registered under the currently applicable United States Securities Act of 1933 ("U.S. Securities Act") or the securities laws of any state or other jurisdiction in the United States and may not be offered, sold or otherwise transferred, directly or indirectly, in or into the United States. The shares are being offered outside of the United States in compliance with Regulation S under the U.S. Securities Act. No offering will be made in the United States. Existing and newly issued shares have neither been approved nor rejected by the United States Securities and Exchange Commission, any state securities authority or other authority in the United States. Moreover, no such authority has evaluated or expressed an opinion on the accuracy or reliability of the Prospectus, the Prospectus Supplement, or this English translation. To assert the contrary is a criminal offense in the United States.

Supplement to the Prospectus

The prospectus supplement in Swedish (the "Prospectus Supplement") has been prepared by AddLife AB (publ), corporate identity no. 556995-8126, ("AddLife" or the "Company") as a supplement to the prospectus regarding the admission of shares to trading on Nasdaq Stockholm and the invitation to subscribe for shares in AddLife (the "Offering"), which was approved by and registered with the Swedish Financial Supervisory Authority (Sw. *Finansinspektionen*) (the "SFSA") on 15 March 2016 (SFSA's journal number 16-599) and published the same day (the "Prospectus"). The Prospectus Supplement constitutes a part of, and shall be read together with, the Prospectus. The definitions in the Prospectus shall apply to the Prospectus Supplement.

The Prospectus Supplement has been prepared in accordance with Chapter 2, Section 34 of the Swedish Financial Instruments Trading Act (1991:980) and has been approved by and registered with the SFSA on 5 April 2016 (SFSA's journal number 16-4400). The Prospectus Supplement was published on 5 April 2016. This English translation of the Prospectus Supplement has not been approved by or registered with any regulatory authority. The Prospectus Supplement and the Prospectus are available at the Company's website, www.add.life, Handelbanken's website, www.handelsbanken.se/investeringserbjudande, and the SFSA's website, www.fi.se. The Prospectus Supplement has been prepared in a Swedish version and this English translation thereof. In the event of any inconsistency between the versions, the Swedish version shall prevail.

The Prospectus Supplement has been prepared by reason of the decision of the board of directors of AddLife regarding the terms and conditions of the issue of shares in the Company pursuant to the Offering (the "Issue") and that Swedbank Robur Fonder, Lannebo Fonder, SEB Investment Management, Odin Fonder and AMF has declared their intention to subscribe for their *pro rata* shares in the Issue, by reason of that AddLife has signed agreements to acquire the companies V-Tech AB and Esthe-Tech AB and by reason of that AddLife has signed an agreement to represent Leica Biosystems' operations in Sweden and Denmark. The terms and conditions of the Issue and the declarations of intent have been published by way of a press release on 30 March 2016. The acquisitions of V-Tech AB and Esthe-Tech AB have been published by way of a press release on 17 March 2016. That AddLife has signed an agreement to represent Leica Biosystems' operations in Sweden and Denmark has been published by way of a press release on 4 April 2016.

Summary of the terms and conditions of the Issue

- The subscription price in the Issue has been set at SEK 61 per share of Class A and Class B.
- In total, 202,353 shares of Class A and 4,721,065 shares of Class B will be offered in the Issue.
- The maximum increase of the share capital will amount to SEK 10,029,188.97, corresponding to a maximum dilution of approximately 20 percent of the share capital and 20 percent of the votes in the Company. The dilution has been calculated as the maximum number of shares and votes that may be issued divided by the maximum total number of shares and votes in the Company after the Issue.
- The preferential right in the Issue is exercised on the basis of subscription rights. Every existing share of Class A in AddLife will entitle to one (1) subscription right for shares of Class A. Four (4) subscription rights for subscription of shares of Class A will entitle to subscribe for one (1) new share of Class A. Every existing share of Class B in AddLife will entitle to one (1) subscription right for shares of Class B. Four (4) subscription rights for subscription of shares of Class B will entitle to subscribe for one (1) new share of Class B.

Declarations of intent from Swedbank Robur Fonder, Lannebo Fonder, SEB Investment Management, Odin Fonder and AMF

Swedbank Robur Fonder, Lannebo Fonder, SEB Investment Management, Odin Fonder and AMF, which together hold 32.2 percent of the share capital, have expressed their support for the Issue and their intention to subscribe for their *pro rata* shares of the Issue. Together with the subscription undertakings signed earlier, the Issue is covered by declarations of intent and subscription undertakings corresponding to 50.7 percent of the rights issue amount. The declarations of intent are not legally binding.

The acquisitions of V-Tech AB and Esthe-Tech AB

V-Tech markets and sells a product range focusing on surgery, in particular on vascular surgery. It also represents several leading suppliers in its speciality area. Its customers operate mainly in public healthcare in Sweden, Norway and Finland. Esthe-Tech markets and sells specialist products for aesthetic and plastic surgery, and its product range is marketed primarily to authorised practitioners in private healthcare. The two companies have

11 employees and combined sales of around SEK 50 million. The acquisitions represent an expansion above all in the area of vascular surgery, strengthening AddLife's position in an attractive segment of the Nordic market. Ownership will become effective on 1 April 2016. The Company estimates that the acquisitions will have a marginally positive impact on AddLife's earnings per share.

AddLife has signed an agreement to represent Leica Biosystems' operations in Sweden and Denmark

On 4 April 2016, AddLife signed an agreement to represent Leica Biosystems for all sales and service functions in Sweden and Denmark. As a part of the transition of the operation, AddLife has acquired the existing business. The business will become an integral part of existing operations within the business area

LabTech. Leica Biosystems is a player in workflow solutions and automation, striving to advance cancer research and diagnostics to improve patients' lives. Leica Biosystems provides a comprehensive product range for each step in the pathology process, from sample preparation and staining to imaging and reporting. Customers are primarily in health care and research laboratories. The business will transfer in May 2016. Leica Biosystems has a turnover of approximately SEK 50 million in Sweden and Denmark. The activities will be built around the strong service and support organization in place in the Triolab companies in the business area LabTech. The Company estimates that the addition of the operations will have a marginally positive impact on AddLife's earnings per share.

Through the Prospectus Supplement, the Prospectus is updated according to the following.

The decision of the board of directors of AddLife regarding the terms and conditions of the Issue leads to the following completions of the Prospectus, in the section "Summary" (page 8 and pages 10–11).

Section C – Securities

C.3	<i>Number of shares in the issuer</i>	A maximum of 202,353 new shares of Class A and 4,721,065 new shares of Class B can be issued through the Issue. After the completion of the Issue, the number of shares in AddLife will be a maximum of 24,617,093 shares, of which a maximum of 1,011,766 are shares of Class A and a maximum of 23,605,327 are shares of Class B.
------------	---------------------------------------	---

Section E – Offering

E.3	<i>Terms and conditions of the Offering</i>	<p>Allotment of shares in the Issue</p> <p>The preferential right in the Issue is exercised on the basis of subscription rights. Every existing share of Class A in AddLife will entitle to one (1) subscription right for shares of Class A. Four (4) subscriptions rights for subscription of shares of Class A will entitle to subscribe for one (1) new share of Class A. Every existing share of Class B in AddLife will entitle to one (1) subscription right for shares of Class B. Four (4) subscriptions rights for subscription of shares of Class B will entitle to subscribe for one (1) new share of Class B.</p> <p>Subscription price</p> <p>The subscription price in the Issue has been set at SEK 61 per share of Class A and Class B.</p>
E.6	<i>Dilution</i>	The maximum increase of the share capital will amount to SEK 10,029,188.97, corresponding to a maximum dilution of approximately 20 percent of the share capital and 20 percent of the votes in the Company. The dilution has been calculated as the maximum number of shares and votes that may be issued divided by the maximum total number of shares and votes in the Company after the Issue.

AddLife's acquisition of V-Tech AB and Esthe-Tech AB leads to the following change in the Prospectus, in the section "Summary" (page 3).

Section B – Issuer and guarantor

B.5	<i>Group</i>	The Group comprises the parent company AddLife AB (publ) and 33 directly and indirectly owned subsidiaries, of which around 27 subsidiaries are operational.
------------	--------------	--

The decision of the board of directors of AddLife regarding the terms and conditions of the Issue leads to the following completions of the Prospectus, in the section "Invitation to subscribe for shares in AddLife AB (publ)" (page 20).

- The subscription price in the Issue has been set at SEK 61 per share of Class A and Class B.
- In total, 202,353 shares of Class A and 4,721,065 shares of Class B will be offered in the Issue.

- The maximum increase of the share capital will amount to SEK 10,029,188.97, corresponding to a maximum dilution of approximately 20 percent of the share capital and 20 percent of the votes in the Company. The dilution has been calculated as the maximum number of shares and votes that may be issued divided by the maximum total number of shares and votes in the Company after the Issue.
- The preferential right in the Issue is exercised on the basis of subscription rights. Every existing share of Class A in AddLife will entitle to one (1) subscription right for shares of Class A. Four (4) subscriptions rights for subscription of shares of Class A will entitle to subscribe for one (1) new share of Class A.

Every existing share of Class B in AddLife will entitle to one (1) subscription right for shares of Class B. Four (4) subscriptions rights for subscription of shares of Class B will entitle to subscribe for one (1) new share of Class B.

The decision of the board of directors of AddLife regarding the terms and conditions of the Issue leads to the following completions of the Prospectus, in the section “Terms, conditions and instructions for the Issue” (pages 22–25).

- The subscription price in the Issue has been set at SEK 61 per share of Class A and Class B.
- In total, 202,353 shares of Class A and 4,721,065 shares of Class B will be offered in the Issue.
- The maximum increase of the share capital will amount to SEK 10,029,188.97, corresponding to a maximum dilution of approximately 20 percent of the share capital and 20 percent of the votes in the Company. The dilution has been calculated as the maximum number of shares and votes that may be issued divided by the maximum total number of shares and votes in the Company after the Issue.
- The preferential right in the Issue is exercised on the basis of subscription rights. Every existing share of Class A in AddLife will entitle to one (1) subscription right for shares of Class A. Four (4) subscriptions rights for subscription of shares of Class A will entitle to subscribe for one (1) new share of Class A. Every existing share of Class B in AddLife will entitle to one (1) subscription right for shares of Class B. Four (4) subscriptions rights for subscription of shares of Class B will entitle to subscribe for one (1) new share of Class B.
- The ISIN code for the subscription rights for subscription of shares of Class A is SE0008241715 and the ISIN code for the subscription rights for subscription of shares of Class B is SE0008241749.

The decision of the board of directors of AddLife regarding the terms and conditions of the Issue leads to the following completions of the Prospectus, in the section “The share, share capital and shareholder structure” (pages 67–68).

- In total, 202,353 shares of Class A and 4,721,065 shares of Class B will be offered in the Issue.
- The maximum increase of the share capital will amount to SEK 10,029,188.97, corresponding to a maximum dilution of approximately 20 percent of the share capital and 20 percent of the votes in the Company. The dilution has been calculated as the maximum number of shares and votes that may be issued divided by the maximum total number of shares and votes in the Company after the Issue.
- The ISIN code for the subscription rights for subscription of shares of Class A is SE0008241715 and the ISIN code for the subscription rights for subscription of shares of Class B is SE0008241749.

The declarations of intent from Swedbank Robur Fonder, Lannebo Fonder, SEB Investment Management, Odin Fonder and AMF leads to the following completion of the Prospectus, in the section “Legal considerations and other information” (page 83).

- Swedbank Robur Fonder, Lannebo Fonder, SEB Investment Management, Odin Fonder and AMF, which together hold 32.2 percent of the share capital, have expressed their support for the Issue and their intention to subscribe for their *pro rata* shares of the Issue. Together with the earlier signed subscription undertakings, the Issue is covered by declarations of intent and subscription undertakings corresponding to 50.7 percent of the rights issue amount. The declarations of intent are not legally binding.

AddLife’s acquisition of V-Tech AB and Esthe-Tech AB leads to the following change in the Prospectus, in the section “Legal considerations and other information” (page 80).

As of the date of this Prospectus Supplement, the Company is the parent company of 33 subsidiaries, of which 27 are operative.

AddLife’s acquisition of V-Tech AB and Esthe-Tech AB leads to the following completion of the Prospectus, in the section “Legal considerations and other information” (page 80).

- The legal group structure shall be completed with V-Tech AB and Esthe-Tech AB. The companies are wholly-owned by AddLife Development AB, which is a wholly-owned subsidiary of AddLife AB (publ).

That AddLife has signed an agreement to represent Leica Biosystems’ operations in Sweden and Denmark leads to the following completion of the Prospectus, in the section “Legal considerations and other information” (page 81).

- **Transition of operation**
On 4 April 2016, AddLife signed an agreement to represent Leica Biosystems for all sales and service functions in Sweden and Denmark. As a part of the transition of the operation, AddLife has acquired the existing business. The business will become an integral part of existing operations within the business area LabTech. Leica Biosystems is a player in workflow solutions and automation, striving to advance cancer research and diagnostics to improve patients’ lives. Leica Biosystems provides a comprehensive product range for each step in the pathology process, from sample preparation and staining to imaging and reporting. Customers are primarily in health care and research laboratories. The business will transfer in May 2016. Leica Biosystems has a turnover of approximately SEK 50 million in Sweden and Denmark. The activities will be built around the strong service and support organization in place in the Triolab companies in the business area LabTech. The Company estimates that the addition of the operations will have a marginally positive impact on AddLife’s earnings per share.